Foretinib (GSK1363089): Multikinase Inhibitor for Cancer Research Workflows

Executive Summary: Foretinib (GSK1363089) is a multi-targeted, ATP-competitive inhibitor of receptor tyrosine kinases, including VEGFRs and the HGF/Met pathway, with IC₅₀ values ranging from 0.4–9.6 nmol/L for key targets such as Met and KDR (VEGFR2) (Schwartz 2022). It suppresses tumor growth, migration, and invasion in multiple cancer cell lines at nanomolar concentrations. Foretinib induces G2/M cell cycle arrest and inhibits HGF-induced cell motility. The compound is insoluble in water/ethanol but is soluble at ≥31.65 mg/mL in DMSO, and requires storage at -20°C for stability. In vivo, oral administration of 30 mg/kg reduces tumor burden in ovarian cancer xenograft models (Schwartz 2022).

Biological Rationale

Receptor tyrosine kinases (RTKs) such as VEGFRs, HGFR/Met, and related kinases are critical regulators of angiogenesis, tumor growth, and metastasis (Schwartz 2022). Dysregulation of these pathways drives cancer progression across multiple solid tumor types. Foretinib (GSK1363089) targets these kinases, enabling precise modulation of proliferation, survival, and motility signaling. This broad-spectrum inhibition supports its use in preclinical models to dissect the functional contribution of VEGF and HGF pathways in cancer biology. The compound’s multi-kinase profile also addresses redundancy in signaling, which often contributes to drug resistance in single-target therapies. By inhibiting both VEGFR and HGF/Met axes, Foretinib provides a valuable tool for mechanistic studies and the development of combination strategies in cancer research.

Mechanism of Action of Foretinib (GSK1363089)

Foretinib (GSK1363089) is an ATP-competitive inhibitor that binds the catalytic domain of multiple RTKs. Key targets include:

• HGF/Met receptor (IC₅₀: 0.4–4.0 nmol/L)
• KDR/VEGFR2 (IC₅₀: 0.9–2.7 nmol/L)
• Flt-1, Flt-4 (VEGFR1/3), Ron, KIT, Flt-3, PDGFRα/β, and Tie-2 (IC₅₀: up to 9.6 nmol/L)

Foretinib blocks downstream signaling events such as MAPK and PI3K/AKT pathway activation. This results in the inhibition of tumor cell proliferation, induction of cell cycle arrest at the G2/M phase, and suppression of HGF-induced motility. The compound effectively reduces cell migration and invasion, thereby limiting metastatic potential in vitro and in vivo (Schwartz 2022). Foretinib’s broad inhibition profile is especially suited for elucidating cross-talk and compensatory mechanisms that enable tumor escape from single-pathway inhibitors.

Evidence & Benchmarks

• Foretinib inhibits Met, Ron, KDR, Flt-1, Flt-4, KIT, Flt-3, PDGFRα/β, and Tie-2 with IC₅₀ values between 0.4–9.6 nmol/L in enzymatic assays (Schwartz 2022).
• In murine B16F10 melanoma, PC-3 prostate, A549 lung, and HT29 colon cancer cell lines, Foretinib suppresses tumor cell growth, migration, and invasion at nanomolar concentrations (Schwartz 2022).
• Cellular MET inhibition in vitro is achieved with IC₅₀ values of 21–23 nmol/L (Schwartz 2022).
• Foretinib induces G2/M cell cycle arrest and reduces proliferation, as measured by viability and cell death assays (Schwartz 2022).
• Oral dosing of 30 mg/kg in xenograft mouse models reduces metastatic ovarian tumor nodules and total tumor weight (Schwartz 2022).
• Foretinib is soluble at ≥31.65 mg/mL in DMSO, but insoluble in water and ethanol (APExBIO product page).

For an extended practical guide to real-world assay implementation, see "Foretinib (GSK1363089): Reliable Multikinase Inhibitor for Cell Assays", which details workflow reproducibility. This article expands on those findings by providing structured evidence summaries and mechanistic clarity.

Applications, Limits & Misconceptions

Foretinib is widely used in preclinical oncology for:

• Cell viability and cytotoxicity assays targeting VEGF and HGF/Met pathways
• Studies of cell motility inhibition using HGF-induced migration models
• In vitro and in vivo metastasis models, including ovarian cancer xenografts
• Mechanistic studies on kinase cross-talk and resistance pathways

For evidence-based troubleshooting and Q&A on assay reproducibility, see "Reliable Cancer Cell Assays with Foretinib (GSK1363089): Q&A". This complements the present article by addressing experimental design and data interpretation challenges.

Common Pitfalls or Misconceptions

• Foretinib is not soluble in water or ethanol; using inappropriate solvents may lead to inaccurate dosing or precipitation (APExBIO).
• The compound is for research use only and is not approved for diagnostic or therapeutic applications.
• Prolonged storage or repeated freeze-thaw cycles at temperatures above -20°C can cause degradation and loss of activity.
• Single-pathway inhibition studies may underestimate Foretinib's broad-spectrum effects; pathway cross-talk must be considered.
• Cell line-specific variations may affect sensitivity; titration and validation in each model are required.

For advanced mechanistic insights and troubleshooting, this article extends prior reviews by focusing on experimental boundaries and translational impact.

Workflow Integration & Parameters

Foretinib (GSK1363089) is provided by APExBIO (SKU A2974) for research workflows. It is delivered as a high-purity small-molecule powder. For best results:

• Dissolve in DMSO to create a stock solution at ≥31.65 mg/mL.
• Store aliquots at -20°C and avoid repeated freeze-thaw cycles.
• Use in cell-based assays at concentrations validated for each system (typically 10–100 nM).
• Apply in motility inhibition assays with HGF or VEGF stimulation for robust mechanistic readouts.
• For in vivo studies, oral gavage at 30 mg/kg in compatible animal models is supported by published data (Schwartz 2022).

For product specifications and ordering, visit the Foretinib (GSK1363089) product page.

Conclusion & Outlook

Foretinib (GSK1363089) is a validated, potent ATP-competitive VEGFR and HGFR inhibitor for advanced cancer research applications. Its multi-target profile and robust nanomolar activity across cell and animal models make it a pivotal tool for dissecting angiogenesis and metastasis pathways. Researchers should adhere to recommended handling and storage protocols to maximize experimental reproducibility. Further optimization in multi-pathway inhibition assays and combination studies is expected to enhance translational relevance. For protocol details and advanced troubleshooting, refer to the cited literature and APExBIO.